BioVersys AG | Finanzwire

Basculer en Français

9475	Companies
185442	Keywords
117783	Articles
99298	Press releases

Home
Companies
BioVersys AG

BRIEF

published on 03/14/2025 at 07:05, 8 months 22 days ago

BioVersys Sets March 26 for Full-Year 2024 Financial Results Release

Financial Results Conference Call Biopharmaceutical Antibacterial Products BioVersys
PRESS RELEASE

published on 03/14/2025 at 07:00, 8 months 22 days ago

BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS
BioVersys AG announces reporting date for full-year 2024 financial results and event details, including a conference call and webcast on March 26, 2025. The company focuses on developing novel antibacterial products for MDR bacteria

Financial Results Conference Call BioVersys AG Antibacterial Products MDR Bacteria
BRIEF

published on 03/10/2025 at 07:05, 8 months 26 days ago

BioVersys AG Announces Partial Exercise of Over-Allotment Option

Biopharmaceutical Company SIX Swiss Exchange Over-allotment Option BioVersys IPO Antibacterial Products
PRESS RELEASE

published on 03/10/2025 at 07:00, 8 months 26 days ago

Bioversys announces partial exercise of over-allotment option
BioVersys announces partial exercise of over-allotment option following successful IPO on the SIX Swiss Exchange, raising total gross proceeds of CHF76.7 million

Biopharmaceutical Company IPO Over-allotment Option BioVersys Multidrug-resistant Bacteria
BRIEF

published on 02/11/2025 at 07:05, 9 months 22 days ago

BioVersys Advances BV500 NTM Program with CF AMR Syndicate Support

Cystic Fibrosis BioVersys AG NTM Program LifeArc Support Ansamycin Chemistry
PRESS RELEASE

published on 02/11/2025 at 07:00, 9 months 22 days ago

BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE
BioVersys advances BV500 NTM program with continued support from CF AMR Syndicate, developing therapies for NTM lung disease in CF patients. Company focuses on antibacterial products against MDR bacteria

BioVersys BV500 NTM Program CF AMR Syndicate NTM Lung Disease MDR Bacteria
BRIEF

published on 02/06/2025 at 07:05, 9 months 27 days ago

BioVersys Successfully Completes IPO at CHF 36 per Share

IPO Market Capitalization SIX Swiss Exchange BioVersys AG Antibacterial Drugs
PRESS RELEASE

published on 02/06/2025 at 07:00, 9 months 27 days ago

BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025
BioVersys successfully completes its IPO at CHF 36 per share, listing on SIX Swiss Exchange on February 07, 2025. The biopharmaceutical company focuses on antibacterial products against multidrug-resistant bacteria

IPO SIX Swiss Exchange Antibacterial Products BioVersys CHF 36
BRIEF

published on 01/29/2025 at 07:05, 10 months 7 days ago

BioVersys AG Launches IPO on SIX Swiss Exchange

SIX Swiss Exchange Share Offering BioVersys IPO Clinical Stage Biopharma Antibacterial Products
PRESS RELEASE

published on 01/29/2025 at 07:00, 10 months 7 days ago

BIOVERSYS LAUNCHES IPO ON THE SIX SWISS EXCHANGE AND SETS IPO PRICE AT CHF 36.00 PER SHARE
BioVersys launches IPO on the SIX Swiss Exchange with an IPO price set at CHF 36.00 per share. Offering expected to raise approximately CHF 80 million in gross proceeds including over-allotment option

IPO SIX Swiss Exchange Offering BioVersys CHF 36.00

Accesswire

Published on 12/05/2025 at 02:35, 9 hours 28 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 9 hours 33 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 11 hours 3 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 58 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours 3 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 48 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 10:30, 1 hour 33 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 48 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 22 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 2 hours 33 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany

Les Echos

Published on 12/05/2025 at 08:45, 3 hours 18 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 18 hours 3 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 18 hours 18 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 18 hours 19 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 5 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE